Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Objective: This study aimed to evaluate the association between metformin treatment and the risk of neurodegenerative disease (ND) among elderly adults with type 2 diabetes mellitus (T2DM). Design/Setting/Participants: This retrospective longitudinal cohort study examined the effects of the length of metformin exposure on ND among elderly US veterans with T2DM and insulin treatment using the Veterans Affairs electronic medical record database. Primary and secondary outcome measures: The primary clinical outcome was defined as diagnosis of ND including dementia, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and mild cognitive impairment during the follow-up period. The secondary clinical outcomes were separately measured by AD, PD, HD, dementia and mild cognitive impairment. Result: Adjusted by propensity score weight, a total of 5528 patients (mean age, 63.2±10.9 years; male, 98%; white, 60%) with a median follow-up of 5.2 years were selected. Those with ND or other mental disorders at baseline or who were on insulin for less than two-thirds of the study period were excluded. The incidence rate of ND was 11.48 per 1000 person-years among patients with metformin treatment, compared with 25.45 per 1000 person-years for those without metformin. Compared with no metformin use, 2–4 years and >4 years of metformin exposure were significantly associated with lower risk of ND (adjusted HR (aHR)=0.62, 95% CI 0.45 to 0.85; aHR=0.19, 95% CI 0.12 to 0.31, respectively), while metformin exposure in the first 2 years showed no significant influence. Conclusion: We conclude that long-term metformin therapy (>2 years) was associated with lower incidence of ND among elderly veterans with T2DM. We need to conduct a study with more representative population and more robust method for causal inferences. Further investigation into the mechanism involved is needed along with randomised trials to confirm a potential neuroprotective effect of metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“several clinical studies suggest that long-term metformin therapy is associated with a lower risk of neurodegenerative diseases.524,525”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [524]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Moreira, R. O., Campos, S. C., & Soldera, A. L. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2442 · Cited by 32
Retracted2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“Additionally, costs were estimated at $157–$215 billion in 2010.(5) Type 2 diabetes mellitus (T2DM) is found to precipitate the burden of ND by increasing the risk of all types of dementia, AD and mild cognitive impairment by about 1.”
Cited by
Xian, H., Liu, Y., Rundberg Nilsson, A., Gatchalian, R., Crother, T. R., Tourtellotte, W. G., Zhang, Y., Aleman-Muench, G. R., Lewis, G., Chen, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.004 · Cited by 407
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Storm, C. S., Kia, D. A., Almramhi, M. M., Bandres-Ciga, S., Finan, C., International Parkinson’s Disease Genomics Consortium (IPDGC), Noyce, A. J., Kaiyrzhanov, R., Middlehurst, B., Tan, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26280-1 · Cited by 208
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“In 5528 patients with T2DM, long-term metformin use ( > 2 years) significantly reduced the risk of developing neurodegenerative disorders including dementia, AD, PD, Huntington ’ s disease, and MCI with a median follow-up period of 5.2 years (Shi et al., 2019).”
BackgroundInfluentialAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases
Tsubaki, H., Tooyama, I., & Walker, D. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249357 · Cited by 157
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis
Zhou, J.-B., Tang, X., Han, M., Yang, J., & Simó, R. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154265 · Cited by 117
SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., & Elekhnawy, E. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01125-5 · Cited by 127
Mitophagy and reactive oxygen species interplay in Parkinson’s disease
Xiao, B., Kuruvilla, J., & Tan, E. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00402-y · Cited by 124
Vascular dementia: From pathobiology to emerging perspectives
Morgan, A. E., & Auley, M. T. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102278 · Cited by 116
Ala, M., & Ala, M. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00167 · Cited by 95
Grotemeyer, A., McFleder, R. L., Wu, J., Wischhusen, J., & Ip, C. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878771 · Cited by 90
Metabolic Aspects of Adenosine Functions in the Brain
Garcia‐Gil, M., Camici, M., Allegrini, S., Pesi, R., & Tozzi, M. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.672182 · Cited by 96
Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges
Agostini, F., Masato, A., Bubacco, L., & Bisaglia, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010398 · Cited by 95
Metformin: An old drug against old age and associated morbidities
Salvatore, T., Pafundi, P. C., Morgillo, F., Liello, R. D., Galiero, R., Nevola, R., Marfella, R., Monaco, L., Rinaldi, L., Adinolfi, L. E., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108025 · Cited by 91
True or false? Alzheimer’s disease is type 3 diabetes: Evidences from bench to bedside
Peng, Y., Yao, S.-Y., Chen, Q., Jin, H., Du, M., Xue, Y.-H., & Liu, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102383 · Cited by 96
Self-citationKuate Defo, A., Bakula, V., Pisaturo, A., Labos, C., Wing, S. S., & Daskalopoulou, S. S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15331 · Cited by 75
Tian, S., Jiang, J., Wang, J., Zhang, Z., Miao, Y., Ji, X., & Bi, Y. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3673 · Cited by 79
Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects
Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M., & Batiha, G. E. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01163-7 · Cited by 82
Álvarez, M. M., Cano-Herrera, G., Martínez, M. F. O., Gonzales-Portillo, J. V., Monroy, G. R., Pérez, R. M., Torres-Ríos, J. A., van Tienhoven, X. A., Bernot, E. M. G., Salazar, F. E., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137183 · Cited by 88
The Bewildering Effect of AMPK Activators in Alzheimer’s Disease: Review of the Current Evidence
Assefa, B. T., Tafere, G. G., Wondafrash, D. Z., & Gidey, M. T. (2020) · BioMed Research International · doi:10.1155/2020/9895121 · Cited by 74
Hassan, A. T., Kandel, R. S., Mishra, R., Gautam, J., Alaref, A. A., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.9853 · Cited by 79
Metformin, Cognitive Function, and Changes in the Gut Microbiome
Rosell-Díaz, M., & Fernández‐Real, J. M. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad029 · Cited by 72
Diabetes: a tipping point in neurodegenerative diseases
Santiago, J. A., Karthikeyan, M., Lackey, M., Villavicencio, D., & Potashkin, J. A. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.09.005 · Cited by 72
Parkinson's disease and glucose metabolism impairment
Chen, L., Wang, C., Qin, L., & Zhang, H. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00467-8 · Cited by 58
Overview of Metformin and Neurodegeneration: A Comprehensive Review
Kruczkowska, W., Gałęziewska, J., Buczek, P., Płuciennik, E., Kciuk, M., & Śliwińska, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040486 · Cited by 58
Exploring the dual character of metformin in Alzheimer's disease
Ning, P., Luo, A., Mu, X. L., Xu, Y., & Li, T. X. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108966 · Cited by 53
Promising use of metformin in treating neurological disorders: biomarker-guided therapies
Loan, A., Syal, C., Lui, M., He, L., & Wang, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385286 · Cited by 53
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
Sportelli, C., Urso, D., Jenner, P. G., & Chaudhuri, К. R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00556 · Cited by 51
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 44
The effect of metformin on cognitive function: A systematic review and meta-analysis
Tabatabaei‐Malazy, O., Bandarian, F., Qorbani, M., Mohseni, S., Mirsadeghi, S., Peimani, M., & Larijani, B. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211057304 · Cited by 48
Mechanistic insight into the role of metformin in Alzheimer's disease
Sanati, M., Aminyavari, S., Afshari, A. R., & Sahebkar, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120299 · Cited by 45
Zhang, J., Zhang, X., Sun, Y., Lv, R.-H., Chen, M., & Li, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.984559 · Cited by 52
Geroscience: A Translational Review
Kritchevsky, S. B., & Cummings, S. R. (2025) · JAMA · doi:10.1001/jama.2025.11289 · Cited by 52
Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine
Colosimo, C., Iuliis, A. D., Montinaro, E., Fatati, G., & Plebani, M. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320965 · Cited by 47
Luo, A., Ning, P., Lu, H., Huang, H., Shen, Q., Zhang, D., Xu, F., Yang, L. J., & Xu, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220180 · Cited by 45
Rabieipoor, S., Zare, M., Ettcheto, M., Camins, A., & Javan, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17873 · Cited by 42
Qin, X., Zhang, X., Li, P., Wang, M., Li, Y., Bao, Z., & Liu, Q. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.678649 · Cited by 44
Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
Poor, S. R., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Olloquequi, J., Camins, A., & Javan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090890 · Cited by 44
Hui, E. K., Mukadam, N., Kohl, G., & Livingston, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251319054 · Cited by 39
Protective effect of metformin against rotenone-induced parkinsonism in mice
Wang, D., Chen, A.-D., Wang, Q., Xin, Y., Yin, J., & Jing, Y. (2020) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2020.1741053 · Cited by 38
Fakih, W., Zeitoun, R., AlZaim, I., Eid, A. H., Kobeissy, F. H., Abd‐Elrahman, K. S., & EL‐Yazbi, A. F. (2022) · Obesity · doi:10.1002/oby.23400 · Cited by 40
Soo, S. K., Rudich, P. D., Traa, A., Harris-Gauthier, N., Shields, H. J., & Raamsdonk, J. M. V. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111297 · Cited by 41
Newby, D., Linden, A. B., Fernandes, M., Winchester, L. M., Molero, Y., Sproviero, W., Ghose, U., Li, Q. S., Launer, L. J., van Duijn, C. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003036 · Cited by 37
Isop, L. M., Neculau, A. E., Necula, R. D., Kakucs, C., Moga, M., & Dima, L. (2023) · Pharmaceuticals · doi:10.3390/ph16121714 · Cited by 41
Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus
Huang, K., Chang, Y.-L., Gau, S., Tsai, T., & Lee, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050946 · Cited by 35
Neural circuit changes in neurological disorders: Evidence from in vivo two-photon imaging
Xiong, H., Tang, F., Guo, Y., Xu, R., & Peng, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101933 · Cited by 36
Careful use to minimize adverse events of oral antidiabetic medications in the elderly
Scheen, A. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912735 · Cited by 37
The role of metformin as a treatment for neuropsychiatric illness
Dodd, S., Sominsky, L., Siskind, D. J., Bortolasci, C. C., Carvalho, A. F., Maes, M. H. J., Walker, A. J., Walder, K. R., Yung, A. R., Williams, L. J., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.002 · Cited by 34
Pandey, S., Mangmool, S., Madreiter‐Sokolowski, C. T., Wichaiyo, S., Luangmonkong, T., & Parichatikanond, W. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175896 · Cited by 34
Pleiotropic effects of anti-diabetic drugs: A comprehensive review
Nath, M., Bhattacharjee, K., & Choudhury, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173349 · Cited by 34
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Recent research progress on metabolic syndrome and risk of Parkinson’s disease
Li, L., Liu, S., Zhuang, J.-L., Li, M.-M., Huang, Z., Chen, Y., Chen, X., Chen, C., Lin, S., & Ye, L. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0093 · Cited by 35
Self-citationMitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Yip, J., Chiang, G. S. H., Lee, I. C. J., Lehming-Teo, R., Dai, K., Dongol, L., Wang, L. Y.-T., Teo, D. W. X., Seah, G. T., & Lehming, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010364 · Cited by 31
Gorgich, E. A. C., Parsaie, H., Yarmand, S., Baharvand, F., & Sarbishegi, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113343 · Cited by 32
Meng, X., Du, H., Li, D., Guo, Y., Luo, P., Pan, L., Kan, R., Yu, P., Xiang, Y., Mao, B., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70089 · Cited by 27
Metformin and the risk of dementia based on an analysis of 396,332 participants
Ji, S., Zhao, X., Zhu, R., Dong, Y., Huang, L., & Zhang, T. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221109454 · Cited by 26
Zhang, Y., Zhang, Y., Shi, X., Han, J., Lin, B., Peng, W., Mei, Z., & Yang, L. (2022) · Diabetic Medicine · doi:10.1111/dme.14821 · Cited by 26
Seksaria, S., Mehan, S., Dutta, B. J., Gupta, G. D., Ganti, S. S., & Singh, A. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23330 · Cited by 24
Weinberg, M. S., He, Y., Kivisäkk, P., Arnold, S. E., & Das, S. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230899 · Cited by 25
Sunnarborg, K., Tiihonen, M., Huovinen, M., Koponen, M., Hartikainen, S. A., & Tolppanen, A. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5448 · Cited by 22
Metformin, Cognitive Decline, And Brain Pathology
Sood, A., Capuano, A. W., Wilson, R. S., Barnes, L. L., Kapasi, A., Bennett, D. A., & Arvanitakis, Z. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.10.005 · Cited by 22
Zhuge, F., Zheng, L., Pan, Y., Ni, L., Fu, Z., Shi, J., & Ni, Y. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114689 · Cited by 21
Tang, C., Hao, J., Tao, F., Feng, Q., Song, Y., & Zeng, B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16192 · Cited by 21
Woodfield, A., Gonzales, T., Helmerhorst, E., Laws, S. M., Newsholme, P., Porter, T., & Verdile, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415811 · Cited by 20
Analysis of risk factors for depression in Alzheimer’s disease patients
Yang, H., Hong, W., Chen, L., Tao, Y. K., Peng, Z., & Zhou, H. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1730369 · Cited by 20
Gedawy, A., Al‐Salami, H., & Dass, C. R. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0102 · Cited by 19
Masato, A., Sandre, M., Antonini, A., & Bubacco, L. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210203162617 · Cited by 19
Salem, E. A., Alqahtani, S. M., El‐Shoura, E. A. M., Zaghlool, S. S., Abdelzaher, L. A., Mohamed, S. A. M., Alalhareth, I. S., & Sheref, A. A. M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03920-7 · Cited by 19
Metformin and Dementia Risk: A Systematic Review with Respect to Time Related Biases
Dai, J., Ports, K. D., Corrada, M. M., Odegaard, A., O’Connell, J., & Jiang, L. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220002 · Cited by 19
Mendonça, I. P., de Paiva, I. H. R., Duarte-Silva, E. P., de Melo, M. G., da Silva, R. S., do Nascimento, M. I. X., & Peixoto, C. A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01043-6 · Cited by 18
Kongtawelert, P., Kaewmool, C., Phitak, T., Phimphilai, M., Pothacharoen, P., & Shwe, T. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-15411-3 · Cited by 17
Birajdar, S. V., Mazahir, F., & Yadav, A. K. (2023) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2023.2282990 · Cited by 17
Xue, Y., & Xie, X. (2023) · Biomedicines · doi:10.3390/biomedicines11112935 · Cited by 17
Corraliza-Gómez, M., Vargas-Soria, M., & García-Alloza, M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00894-1 · Cited by 16
From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin
Campagnoli, L. I. M., Varesi, A., Fahmideh, F., Hakimizad, R., Petkovic, P., Barbieri, A., Marchesi, N., & Pascale, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199748 · Cited by 16
Ay, M., Charli, A., Langley, M. R., Jang, A.-Y., Padhi, P., Jin, H., Anantharam, V., Kalyanaraman, B., Kanthasamy, A., & Kanthasamy, A. G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1356703 · Cited by 16
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 18
Unveiling new secrets in Parkinson’s disease: The glycatome
Chegão, A., & Miranda, H. V. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114309 · Cited by 15
Rahman, S. O., Khan, T. M., Iqubal, A., Agarwal, S., Akhtar, M., Parvez, S., Shah, Z. A., & Najmi, A. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121899 · Cited by 15
Pradhan, S. P., Sahu, P. K., & Behera, A. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04696-1 · Cited by 14
Goldman, S. M., Weaver, F. M., Cao, L., González, B., Stroupe, K. T., Colletta, K., Jugnundan, S., Brown, E. G., & Tanner, C. M. (2024) · Movement Disorders · doi:10.1002/mds.30075 · Cited by 15
Lee, H., & Kim, E. Y. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01268-5 · Cited by 15
AMPK activators for the prevention and treatment of neurodegenerative diseases
Neumann, N. R., Thompson, D. C., & Vasiliou, V. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1991308 · Cited by 15
Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Hroudová, J., & Fišar, Z. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111069 · Cited by 13
Mitochondria-targeting by small molecules against Alzheimer's disease: A mechanistic perspective
Pal, C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167617 · Cited by 14
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Salvadè, M., Luca, M. D., & Gardoni, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117862 · Cited by 14
New Insight into Metformin Mechanism of Action and Clinical Application
Yan, Y., Kover, K. L., & Moore, W. V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91148 · Cited by 13
Huang, K., Tsai, Y., Lee, C. B., Gau, S., Tsai, T., Chung, N.-J., & Lee, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050738 · Cited by 15
Chen, P.-C., Hong, C.-T., Chen, W.-T., Chan, L., & Chien, L.-N. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.01.007 · Cited by 12
Powell, M. A., Clark, C. N., Alyakin, A., Vogelstein, J. T., & Hart, B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41505 · Cited by 14
Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study
Tseng, C. (2023) · Otolaryngology · doi:10.1002/ohn.232 · Cited by 12
Polyoxidovanadates as a pharmacological option against brain aging
Díaz, A., Vázquez‐Roque, R. A., Carreto-Meneses, K., Moroni-González, D., Moreno-Rodríguez, J. A., & Treviño, S. (2023) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2023.102256 · Cited by 12
Wu, C., Wang, C., Saskin, R., Shah, B. R., Kapral, M. K., Lanctôt, K. L., Herrmann, N., Cogo‐Moreira, H., MacIntosh, B. J., Edwards, J. D., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13723 · Cited by 12
Xie, Y., Wang, J., Jiang, J., Liu, F., & Zhang, Y. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06965-9 · Cited by 11
Anti-diabetics and the Prevention of Dementia: A Systematic Review
Slouha, E., Ibrahim, F., Rezazadah, A., Esposito, S., Clunes, L. A., & Kollias, T. F. (2023) · Cureus · doi:10.7759/cureus.49515 · Cited by 11
Ashraf, G. M., DasGupta, D., Alam, M. Z., Baeesa, S. S., Alghamdi, B. S. A., Anwar, F., Alqurashi, T. M. A., Sharaf, S. E., Abdulmonem, W. A., Alyousef, M., et al. (2022) · Molecules · doi:10.3390/molecules27144652 · Cited by 10
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Cai, C., Gu, C., Meng, C., He, S., Lhamo, T., Draga, D., Zheng, Z., & Qiu, Q. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03777-0 · Cited by 9
Maciejczyk, A., & Blecharz‐Klin, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118743 · Cited by 10
Metadata
- Authors
- Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L.
- Affiliations
- Tulane University (US)
- Corresponding author
- Shi, Lizheng
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2019-07
- Volume
- 9
- Issue
- 7
- Pages
- e024954
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC6677947
- OpenAlex
- W2964394554
- Cited by
- 144
- References
- 49
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 18 · 2023: 33 · 2022: 28 · 2021: 15 · 2020: 17 · 2019: 1
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institute of General Medical Sciences (U54GM104940)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, neurodegenerative diseases, type 2 diabetes, veterans, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, mild cognitive impairment, insulin therapy, neuroprotection, drug exposure duration
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Metformin, Middle Aged, Retrospective Studies, Risk Factors, United States, Veterans, Comorbidity, Incidence, Proportional Hazards Models, Neurodegenerative Diseases, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.